AZNNEUTRAL

Revenue Growth (YoY)

12.5%

Higher than 78% of Healthcare sector peers

Updated 19h ago

Sector Performance

78th percentile

AZN

12.5%

Sector Median

6.2%

Sector Avg

3.8%

📊

Deep Analysis

AstraZeneca’s current Revenue Growth (YoY) of 12.5% means the company’s sales increased by that percentage over the same quarter last year, indicating the top-line expansion rate.

Among healthcare sector peers, this figure sits above the sector median of 6.2% and ranks in the 76th percentile, meaning the company is growing faster than roughly three-quarters of its peers. The trend data are not available (N/A) for both the year-over-year change and the quarter-over-quarter change, as only a single historical value of 12.5% is recorded. Because there is no trend information, the investment risk or opportunity cannot be assessed from directionality; the high level alone suggests above-average growth but offers no signal about momentum. This metric supports the overall NEUTRAL verdict — the strong growth relative to peers is a positive, yet the absence of a trend prevents a bullish or bearish tilt, aligning with a neutral stance.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about AZN?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does AZN's Revenue Growth (YoY) compare to its sector?

AZN's Revenue Growth (YoY) of 12.5% compares to a Healthcare sector median of 6.2%, placing it in the 78th percentile.

Who are AZN's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: AMGN (5.8%), CPRX (5.6%), HIMS (3.8%), BAX (2.9%), BMY (2.6%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.